SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 1/17/2017 3:53:57 PM - Followers: 139 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Initial Statement of Beneficial Ownership (3) 01/17/2017 07:29:52 AM
#4265   Frost's bio is promising for RXII. The Other Guy 01/17/17 03:53:57 PM
#4264   from what I've seen with Frost normally some UHD 01/17/17 03:21:05 PM
#4263   About a year ago (going from memory) Geert The Other Guy 01/17/17 03:07:36 PM
#4262   Oh yea mean weimeraner 01/17/17 09:33:04 AM
#4261   insiders disclosing their positions, something big coming? UHD 01/17/17 09:25:02 AM
#4260   Very true, shorts are right behind us. Yes, Pontius Antipas 01/16/17 11:05:20 PM
#4259   Tomorrow will see the confirmation of the move, vinsky_ever_trader 01/16/17 10:28:02 PM
#4258   There is a high probability we see a The Other Guy 01/16/17 04:23:41 PM
#4257   * * $RXII Video Chart 01-13-17 * * ClayTrader 01/13/17 05:18:07 PM
#4256   Weekend effect, will bounce hard next week :-) vinsky_ever_trader 01/13/17 04:22:55 PM
#4255   Gap filled look at these clowns go mean weimeraner 01/13/17 03:53:31 PM
#4254   Desperately filling that gap, taking all the money mean weimeraner 01/13/17 03:12:34 PM
#4253   Agree added tf outta these mean weimeraner 01/13/17 01:59:33 PM
#4252   $1 soon :-) vinsky_ever_trader 01/13/17 01:53:28 PM
#4251   Not realtime tho mean weimeraner 01/13/17 11:44:57 AM
#4250   Fidelity shows the short position at 3.6%, which senderos 01/13/17 11:37:00 AM
#4249   No but they fked mean weimeraner 01/13/17 11:29:54 AM
#4248   anyone know the short position in this? madras50 01/13/17 11:27:44 AM
#4247   ADDING HERE :-) vinsky_ever_trader 01/13/17 11:26:51 AM
#4246   You know what I mean mean weimeraner 01/13/17 10:23:16 AM
#4245   It is apparent that other pharmas and investment senderos 01/13/17 10:22:47 AM
#4244   Maybe as overall volume. As a percentage of The Other Guy 01/13/17 10:09:52 AM
#4243   Will see record high vol today mean weimeraner 01/13/17 09:42:36 AM
#4242   RXII why not. Every thing else is. PAC 01/13/17 09:12:16 AM
#4241   Volume... stock1ace1 01/13/17 09:04:54 AM
#4240   The skeptic in me says we don't close The Other Guy 01/13/17 08:59:06 AM
#4239   Any guess how high this might go today? senderos 01/13/17 08:54:08 AM
#4238   Edit: Opko health The Other Guy 01/13/17 08:53:09 AM
#4237   Polo health takes 5.11% stake in RXII The Other Guy 01/13/17 08:50:19 AM
#4236   Over a million shares traded in PM. The Other Guy 01/13/17 08:43:16 AM
#4235   RXII $1 now. ClearlyStocks 01/13/17 08:19:17 AM
#4234   RXII breaks $1 and it's on! ClearlyStocks 01/13/17 08:16:41 AM
#4233   3x1 is my guess. One of them being The Other Guy 01/09/17 07:14:20 PM
#4232   so... jaytea 01/09/17 05:26:33 PM
#4231   I hear ya, and I agree. senderos 01/09/17 04:43:49 PM
#4230   I notice CEO's of small biotech companies use The Other Guy 01/09/17 01:04:30 PM
#4229   According to Geert on one of the earnings sabaidii2 01/09/17 12:21:30 PM
#4228   I hope this is not the only partnership/acquisition The Other Guy 01/09/17 12:15:01 PM
#4227   It is always good when a deal is senderos 01/09/17 12:08:19 PM
#4226   How is this "excellent news?" We knew The Other Guy 01/09/17 11:16:36 AM
#4225   Excellent news! senderos 01/09/17 08:46:17 AM
#4224   RXi Pharmaceuticals Completes Acquisition of MirImmune, stock up BioPharma 01/09/17 08:14:42 AM
#4223   Agreed. The way management set up the end The Other Guy 01/03/17 10:56:32 AM
#4222   The only way I see that happening is Inoviorulez 12/31/16 04:51:18 PM
#4221   You both may be correct, but I predict senderos 12/31/16 01:40:21 PM
#4220   I concur million_dollar_mafia 12/31/16 12:59:20 PM
#4219   They have been doing presentations for the past Inoviorulez 12/31/16 08:23:31 AM
#4218   RXi Pharmaceuticals to Present at the 9th Annual senderos 12/27/16 05:51:26 AM
#4217   Thoughts. The company has not given us any reason reyesrocks22 12/25/16 09:04:06 PM
#4216   Before any True Believers respond, let me: You're sabaidii2 12/25/16 07:36:41 PM